|
SMC5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.38220000001077E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.30379999999597E-05 |
| Normal-vs-Stage2 |
2.18809999996683E-06 |
| Normal-vs-Stage3 |
2.03839999999289E-05 |
| Normal-vs-Stage4 |
3.29749999972151E-07 |
| Stage1-vs-Stage2 |
4.040200E-02 |
| Stage1-vs-Stage3 |
2.896600E-01 |
| Stage1-vs-Stage4 |
2.327500E-02 |
| Stage2-vs-Stage3 |
2.630800E-01 |
| Stage2-vs-Stage4 |
9.140800E-01 |
| Stage3-vs-Stage4 |
1.937400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.15839999995193E-06 |
| Normal-vs-AfricanAmerican |
1.905860E-02 |
| Normal-vs-Asian |
1.981320E-03 |
| Caucasian-vs-AfricanAmerican |
5.310000E-01 |
| Caucasian-vs-Asian |
5.459600E-01 |
| AfricanAmerican-vs-Asian |
8.801000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.10539999997883E-06 |
| Normal-vs-Female |
1.5832599999932E-05 |
| Male-vs-Female |
3.876200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.010000E-04 |
| Normal-vs-Age(41-60Yrs) |
4.6657000000172E-06 |
| Normal-vs-Age(61-80Yrs) |
1.44140000046811E-07 |
| Normal-vs-Age(81-100Yrs) |
2.156700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.286640E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.598600E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.546210E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.266590E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.607400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.408600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.562630E-01 |
| Classical-VS-Follicular |
7.825900E-04 |
| Classical-VS-Other |
2.391400E-01 |
| Classical-VS-Normal |
2.612600E-04 |
| Tall-VS-Follicular |
2.968000E-01 |
| Tall-VS-Other |
6.451400E-01 |
| Tall-VS-Normal |
1.996400E-04 |
| Follicular-VS-Other |
9.155000E-01 |
| Follicular-VS-Normal |
2.14920000018992E-07 |
| Other-VS-Normal |
9.978400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.15650000266055E-08 |
| Normal-vs-N1 |
1.991750E-04 |
| N0-vs-N1 |
5.908000E-01 |
|
|
